Activated matrix metalloproteinases, including MMP3 and MMP12 that are increased in the inflamed mucosa of patients with IBD, have a wide range of substrates including the anti-TNFα biologics infliximab, adalimumab and etanercept10. This evidence concerns the gene MMP12 and inflammatory bowel disease.